Akshay Gupte, PhD, MBBS, MSPH, PhD

Role:

Faculty

Assistant Professor

Dr. Gupte is Assistant Professor of Global Health at the Boston University School of Public Health. His research is focused on the intersection of infectious and chronic lung diseases in low- and middle-income settings. He is the PI/multi-PI of NIH funded Indo-US collaborative studies to describe the epidemiology and pathogenesis of lung impairment in tuberculosis (TB)/HIV/diabetes, measure its impact on poor clinical outcomes, and identify therapeutic and programmatic interventions to improve post-TB lung health and longevity. Dr. Gupte serves on several multi-national TB/HIV research consortia, such as the TB Transformative Science Working Group of the AIDS Clinical Trials Group (ACTG), Lung Health Working Group of the International Epidemiology Databases to Evaluate AIDS (IeDEA) network, and is Chairperson of the Clinical and Epidemiology Working Group of the RePORT-India TB Research Consortium. He is a 2017 Fogarty Fellow and recipient of the Arthur M. Dannenberg, Jr., Award for excellence in TB research. Dr. Gupte completed his medical training in India, Master’s and Doctoral training from the Johns Hopkins Bloomberg School of Public Health, and has previously served as faculty in the Division of Infectious Diseases, Johns Hopkins School of Medicine.

Studies/Projects
Publications
Scholars
News

Assessing prevalence and risk of lung morbidities including lung nodules and cancer using non contrast CT among PLHIV in Pune, India

Post Date:

2022-11-25

|

Countries:

|

Clinical Sites:

Primary objective Determine the prevalence of pulmonary nodules, including lung cancer using NCCT. Determine the risk of pulmonary nodules, including lung cancer using NCCT. Evaluate the association of smoking, immune suppression, ART, and TB with the prevalence and risk of NCCT-diagnosed pulmonary...

Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease

Post Date:

2020-08-23

|

Countries:

|

Clinical Sites:

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort (Cohort B). Immunological profiling of TB antigen induced biosignatures, profiling of transcriptional and proteomic biosignatures should provide novel insights into the...

Epidemiology and Clinical Outcomes of COVID-19 in India (ECO-19)

Post Date:

2020-07-09

|

Countries:

|

Clinical Sites:

This study was terminated May 25, 2021 This is a prospective cohort study of adults with suspected COVID-19 to address key knowledge gaps in the epidemiology of disease severity and poor clinical outcomes in India. Results from this study may help clinicians in India focus limited health resources...

Tuberculosis (TB) Aftermath

Post Date:

2020-06-05

|

Countries:

|

Clinical Sites:

Drs. Vidya Mave and Jonathan Golub are co-PIs and Dr. Barthwal from DY Patil Medical College is local site PI for this study. TB Aftermath seeks to provide evidence for an effective and scalable strategy targeting HHs of treated TB cases, a high priority of the NTEP. Purpose To compare the...

Prevalence of Risk Factors for Lung Cancer and Facilitators and Barriers for Tobacco Cessation among People Living with HIV

Post Date:

2020-04-01

|

Countries:

|

Clinical Sites:

India has the world’s third largest HIV epidemic, with 2.1 million people currently living with HIV and an additional 90,000 new infections each year.[29] At the same time, expansion of the HIV response under India’s premier governmental agency - the National AIDS Control Organization (NACO), has...

Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)

Post Date:

2019-12-17

|

Countries:

|

Clinical Sites:

Primary Objective: This study is being conducted in Brazil, Cambodia, China, Ethiopia, Ghana, Haiti, India, Indonesia, Kenya, Malawi, Mozambique, South Africa, Tanzania, and Zimbabwe. The overall goal is to reduce TB incidence among (1) people living with HIV who are on antiretroviral therapy, and...

Markers of Lung Impairment in HIV-TB Coinfected Indian Adults

Post Date:

2019-12-11

|

Countries:

|

Clinical Sites:

Objectives/Aims We will compare the degree of lung impairment between HIV-TB co-infected adults (HIV-TB group) and TB cases without HIV co-infection (TB group) who successfully complete TB therapy. We hypothesize that the HIV-TB group will have a greater degree of lung...

Inflammasome Genetics and Tuberculosis Treatment Outcomes

Post Date:

2019-11-07

|

Countries:

|

Clinical Sites:

Dr. Amita Gupta is a Co-PI on this study. STUDY DESIGN We will conduct a retrospective case-cohort study nested within the CTRIUMPH and EDOTS cohorts to address our study objectives. This will enable us to measure the association of polymorphisms with multiple clinical outcomes simultaneously and...

Molecular Signatures of Tuberculosis-Diabetes Interaction: Metabolomics Study

Post Date:

2018-06-15

|

Countries:

|

Clinical Sites:

This study is using stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium. Type 2 diabetes mellitus (DM...

Molecular Signatures of Tuberculosis-Diabetes Interaction: Transcriptomics Study

Post Date:

2018-06-15

|

Countries:

|

Clinical Sites:

This study is using stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium. Type 2 diabetes is an...

Lipid Mediators of Inflammation in TB and TB-Diabetes

Post Date:

2017-10-02

|

Countries:

|

Clinical Sites:

This study was terminated August 1, 2019. It was funded and conducted under the U.S. National Institutes of Health and is nested within Impact of Diabetes on TB Treatment Outcomes. Dr. Jonathan Golub was the PI. Studies have shown that individuals with...

Investigating Maternal Antibodies to Modify Infant Tuberculosis Acquisition

Post Date:

2017-08-29

|

Countries:

|

Clinical Sites:

New study in Pune, India, aims to identify the profile of TB antibodies between mothers and infants, and to see if the presence of antibodies lowers risk of infant infection.

Validation of Transcriptional Signature to Predict Active TB Disease among Advanced HIV Patients

Post Date:

2017-08-15

|

Countries:

|

Clinical Sites:

This study was terminated June 20, 2021. There have been tremendous advances in the diagnosis of patients with tuberculosis (TB) based on nucleic acid amplification of bacteria in the sputum. The GenXpert MTB/RIF provides results in 2 hours. However, in HIV-infected sputum...

Association of Lipid Mediators of Inflammation with TB Treatment Outcomes

Post Date:

2017-08-03

|

Countries:

|

Clinical Sites:

This study was terminated July 22, 2019. This study used stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB...

Residual Respiratory Impairment Following Pulmonary Tuberculosis

Post Date:

2015-09-13

|

Countries:

|

Clinical Sites:

This study is conducted by the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH) under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium. Many TB patients have...

Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH)

Post Date:

2013-09-28

|

Countries:

|

Clinical Sites:

Collaboratively funded by the US NIH, India’s Department of Biotechnology [DBT], and Indian Council of Medical Research, the Cohort for TB Research by the Indo-US Medical Partnership (C-TRIUMPH) is an Indo-US research consortium that is part of RePORT India, a countrywide consortium for TB...

BWI CTU: Baltimore-Washington-India Clinical Trials Unit

Post Date:

2007-02-02

|

Countries:

|

Clinical Sites:

Comprising clinical trial sites at Johns Hopkins Medicine in Baltimore, Whitman Walker Health in Washington, DC, and the BJGMC-CCGHE collaboration in Pune, India, the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU) is one of only 25 international HIV/TB clinical trial sites funded by the...

Characterising cause of death among people treated for drug-susceptible TB in India

Post Date:

2023-01-12

|

Countries:

Publication:

The International Journal of Tuberculosis and Lung Disease

Annually, 1.5 million people die of TB.1 India has thehighest burden of TB,1 and in 2020, the case fatality ratio (CFR) among people with drug-susceptible TB was 4.3%.2 Even after treatment, mortality is more than two-fold higher among people with prior TB compared to the general population.3...

Randomized Clinical Trial of High Dose Rifampicin with or without Levofloxacin versus Standard of Care for Paediatric Tuberculous Meningitis: The TBM-KIDS Trial

Post Date:

2022-10-29

|

Countries:

Publication:

Clinical Infectious Diseases

Background Pediatric tuberculous meningitis (TBM) commonly causes death or disability. In adults, high-dose rifampicin may reduce mortality. The role of fluoroquinolones remains unclear. There have been no antimicrobial treatment trials for pediatric TBM. Methods TBM-KIDS was a phase 2 open-label...

Clinical and Immunological Markers of Pulmonary Impairment Among People With HIV in India

Post Date:

2022-10-06

|

Countries:

Publication:

Open Form Infectious Diseases

Dr. Akshay Gupte and team found females were 7 times more likely to have restrictive spirometry pattern and 22 times more likely to have preserved ratio impaired spirometry, compared with men.

Concomitant pulmonary disease is common among patients with extrapulmonary TB

Post Date:

2022-08-12

|

Countries:

|

Clinical Sites:

Publication:

International Journal of Tuberculosis and Lung Disease

Dr. Shivakumar and his group discovered that a high proportion of patients classified as EPTB in India have concomitant PTB. Their results support the need for improved symptom and CXR screening, and recommends routine sputum TB microbiology screening of all Indian patients with EPTB.

Clinical and Immunological Markers of Pulmonary Impairment among People with HIV(PWH) in India

Post Date:

2022-05-12

|

Countries:

Publication:

Open Forum Infectious Diseases

Background Despite anti-retroviral therapy, chronic lung diseases remain an important source of morbidity and mortality in people with HIV (PWH). We sought to identify clinical and immunological markers of pulmonary impairment among PWH in India. Methods 210 adult PWH receiving antiretroviral...

Host lipidome and tuberculosis treatment failure

Post Date:

2022-01-06

|

Countries:

Publication:

European Respiratory Journal

Introduction: Host lipids play important roles in tuberculosis (TB) pathogenesis. Whether host lipids at TB treatment initiation (baseline) affect subsequent treatment outcomes has not been well characterised. We used unbiased lipidomics to study the prospective association of host lipids with TB...

Increased Moxifloxacin Dosing among MDR-TB Patients with Low-Level Resistance to Moxifloxacin did not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India

Post Date:

2021-12-23

|

Countries:

Publication:

Open Forum Infectious Diseases

Background Mycobacterium tuberculosis (Mtb) strains resistant to isoniazid and rifampin (multidrug-resistant tuberculosis [MDR-TB]) are increasingly reported worldwide, requiring renewed focus on the nuances of drug resistance. Patients with low-level moxifloxacin resistance may benefit from higher...

Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study

Post Date:

2021-11-08

Publication:

The European Respiratory Journal

Dr. Akshay Gupte and colleagues discovered that elevated IL-6 can predict poor treatment outcomes, showcasing a need for including IL-6 in clinical screenings.

Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India

Post Date:

2021-04-01

|

Countries:

|

Clinical Sites:

Publication:

Open Forum Infectious Diseases

Background Diabetes mellitus (DM) increases the risk of tuberculosis (TB) disease. Knowledge of the impact of DM on TB treatment outcomes is primarily based on retrospective studies. Methods We conducted a prospective cohort study of new pulmonary TB patients with and without DM (TB-DM and TB only...

Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men

Post Date:

2021-03-10

|

Countries:

|

Clinical Sites:

Publication:

International Journal of Tuberculosis and Lung Disease

This study by Samyra Cox and colleagues highlights the need for integrating effective alcohol interventions into TB care.

Higher interleukin-6 levels and changes in transforming growth factor-β are associated with lung impairment in pulmonary tuberculosis

Post Date:

2021-01-18

|

Countries:

Publication:

ERJ Open Resource

Higher levels of IL-6 and slow-to-resolve TGF-β are associated with lung impairment in treated tuberculosis. These results have important implications for clinical trials of immunomodulatory therapies to prevent tuberculosis-associated lung disease. http://openres.ersjournals.com/lookup/doi/...

Higher IL-6 Levels and Changes in TGF-β are Associated with Lung Impairment in Pulmonary Tuberculosis

Post Date:

2021-01-08

|

Countries:

Publication:

ERJ

Pulmonary tuberculosis (PTB) is associated with granuloma formation, necrosis and cavitation in lung tissue. Lung injury in PTB can persist despite microbiological cure and is associated with chronic obstructive pulmonary disease (COPD) independent of smoking exposure[1]. Furthermore, pulmonary...

Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children

Post Date:

2020-11-11

|

Countries:

Publication:

Scientific Reports

Pediatric tuberculosis (TB) remains a major global health problem. Improved pediatric diagnostics using readily available biosources are urgently needed. We used liquid chromatography-mass spectrometry to analyze plasma metabolite profiles of Indian children with active TB (n = 16) and age- and sex...

Tuberculosis preventive treatment should be considered for all household contacts of pulmonary tuberculosis patients in India

Post Date:

2020-07-29

|

Countries:

|

Clinical Sites:

Publication:

PLoS One

PLoS One: Dr. Mandar Paradkar and colleagues conducted a CTRIUMPH study that supports TB preventive therapy for all household contacts of pulmonary TB patients in India

Chronic Obstructive Pulmonary Disease Endotypes in Low- and Middle-Income Country Settings: Precision Medicine for All

Post Date:

2020-07-15

Publication:

Am J Respir Crit Care Med

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease marked by largely irreversible airflow obstruction due to small airway obstruction and emphysema that results from complex gene–environment interactions over the lifespan of an individual. Although the clinical definition of...

Once-Weekly Rifapentine and Isoniazid (3HP) Among Patients with HIV Taking Dolutegravir-based Antiretroviral Therapy: A Phase I/II Clinical Trial

Post Date:

2020-06-01

Publication:

The Lancet HIV

Background Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV. However, a small previous trial of such therapy with dolutegravir in healthy, HIV-...

Once-weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Patients With HIV Taking Dolutegravir-Based Antiretroviral Therapy: A Phase 1/2 Trial

Post Date:

2020-03-30

Publication:

Lancet HIV

Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV.

Lipid mediators of inflammation and resolution in individuals with tuberculosis and tuberculosis-diabetes

Post Date:

2019-11-11

Publication:

Prostaglandins and Other Lipid Mediators

Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the resolution...

MAL adaptor (TIRAP) S180L polymorphism and severity of disease among tuberculosis patients

Post Date:

2019-10-31

|

Countries:

|

Clinical Sites:

Publication:

Infection, Genetics, and Evolution

Infection, Genetics, and Evolution : We investigated the association of TIRAP variants with severity of TB disease and IP-10 production in humans, which may be useful in predicting poor clinical outcome

Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India

Post Date:

2019-10-29

|

Countries:

|

Clinical Sites:

Publication:

BMC Infectious Diseases

In this study among people living with HIV, Akshay Gupte and colleagues found that the risk of acquiring tuberculosis was higher in those receiving first-line antiretrovial therapy versus those receiving second-line medications.

Pages

Abhilash Suresh

Baltimore, Maryland

Abhilash Suresh is a BS candidate in biomedical engineering at Johns Hopkins Whiting School of Engineering (2018), who worked with Drs. Akshay Gupte and Shri Vijay Bala Yogendra Shivakumar on the C-TRIUMPH substudy on Residual Respiratory Impairment Following Pulmonary Tuberculosis. During May and June 2016 he conducted a field placement in Chennai, India, at the National Institute for Research in Tuberculosis where he worked under Dr. Shivakumar. Awards 2016 Global Health Established Field Placement Grant ...

Researchers Identify Biomarker that Heralds Poor Outcomes in TB Patients

Post Date:

2021-11-09

Dr. Akshay Gupte and colleagues discovered that elevated IL-6 can predict poor treatment outcomes, showcasing a need for including IL-6 in clinical screenings.

Cured TB patients run risk of lung disease: Study

Post Date:

2019-06-03

Source:

The Telegraph (India)

Dr. Akshay Gupte comments on recent findings that many who've recovered from TB face increased risk of COPD

Celebrating Johns Hopkins Medicine's impact in India

Post Date:

2017-12-13

Source:

The Campaign for Johns Hopkins Medicine

In 4 years, the CCGHE has tripled its capacity for conducting research on grave health threats, thanks to strong philanthropic support.

Amita Gupta and colleagues discuss female leadership in academic global health

Post Date:

2017-05-04

Drs. Gupta, Manabe, Mathad discuss need for more women in global health leadership at CUGH's annual meeting.

Advancing Global TB Research through RePORT

Post Date:

2016-02-29

Regional Prospective Observational Research for Tuberculosis (RePORT) International is a large, international tuberculosis research effort being undertaken by 4 regional consortia: RePORT Brazil, RePORT South Africa, RePORT Indonesia, and RePORT India. While each region collects and maintains...